Ventyx Biosciences reported Phase 2 biomarker results showing its oral NLRP3 inhibitor VTX3232 produced an almost 80% reduction in hsCRP within one week and a 78% monotherapy reduction over 12 weeks versus placebo. The trial of 175 patients also showed statistically significant decreases in IL‑6, Lp(a), fibrinogen and liver‑inflammation metrics, and the drug was well tolerated. The San Diego biotech said VTX3232 was safe as monotherapy and when combined with semaglutide; the combination delivered additional reductions in inflammation and liver parameters in patients with baseline liver fat. Investors reacted, driving an ~84% intraday stock jump on the readout. If replicated in larger outcomes trials, a rapid, robust anti‑inflammatory profile in cardiometabolic populations could position an NLRP3 inhibitor as a companion to weight‑loss and metabolic therapies and a potential entrant into cardiovascular risk‑reduction strategies.